Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia

• Status: Completed
• Trial end date: 2016-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to find out how well participants with relapsed or refractory ALL respond to treatment with an etoposide- and teniposide-based induction chemotherapy regimen and what the side effects are.

Primary Objectives:

• To estimate the response rate for patients with refractory or relapsed ALL.

• To estimate the survival rate of patients with refractory or relapsed ALL treated with risk-directed therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: St. Jude Children's Research Hospital
• Treatments: 6-Mercaptopurine; Asparaginase; BB 1101; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Etoposide; Etoposide phosphate; Mercaptopurine; Methotrexate; Mitoxantrone; Pegaspargase; Teniposide; Vinblastine; Vincristine

Criteria

Inclusion Criteria

• Childhood ALL in first relapse OR in first hematological relapse after an extramedullary relapse, OR not attaining a complete remission with frontline therapies, OR lymphoblastic leukemia in first relapse.

• Patients must be 21 years of age or younger

• Informed consent explained to and signed by parent/legal guardian.

Exclusion Criteria

• Life expectancy less than 8 weeks

• Patients with mature B cell ALL